drugset
drugset / Trial / NCT04026750

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

NCT04026750 ↗

Phase 1 Terminated 5 enrolled High Point Clinical Trials Center Ferox Therapeutics · collab
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The primary objective of this study is to determine the safety, tolerability and pharmacodynamics of pitolisant in patients with Type 1 Diabetes

Timeline

Start
2019-09-15
Primary completion
2020-02-16
Completion
2020-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Pitolisant Small molecule — Oral

Indications

hypoglycemia type 1 diabetes mellitus